ABBVIE
🇫🇷France
Juvenile Idiopathic Arthritis (JIA) Registry
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 849
- Registration Number
- NCT00783510
- Locations
- 🇺🇸
University of Louisville /ID# 23507, Louisville, Kentucky, United States
🇺🇸Arthritis Care Spec. of MD /ID# 21961, Ellicott City, Maryland, United States
🇺🇸North Shore University Hospital /ID# 21022, New Hyde Park, New York, United States
A Phase 1 Study of ABT-869 in Subjects With Solid Tumors
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 18
- Registration Number
- NCT00718380
Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 133
- Registration Number
- NCT00696904
Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 262
- Registration Number
- NCT00660673
- Locations
- 🇺🇸
Univ Maryland School Medicine /ID# 49934, Baltimore, Maryland, United States
🇺🇸Johns Hopkins University /ID# 49937, Baltimore, Maryland, United States
🇺🇸Charlotte Neurological Service /ID# 49916, Port Charlotte, Florida, United States
A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 33
- Registration Number
- NCT00654758
Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT00650156
- Locations
- 🇨🇳
Site Reference ID/Investigator# 7181, Shanghai, China
An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 155
- Registration Number
- NCT00619866
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 41
- Registration Number
- NCT00526617
A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT00481091
- Locations
- 🇺🇸
Dana-Farber Cancer Institute /ID# 5547, Boston, Massachusetts, United States
🇬🇧Leicester Royal Infirmary /ID# 15081, Leicester, England, United Kingdom
🇺🇸Moores Cancer Center at UC San Diego /ID# 5566, La Jolla, California, United States
Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 252
- Registration Number
- NCT00437658
© Copyright 2024. All Rights Reserved by MedPath